2 feature selection Search Results


a/flus (selective use; >1 without oncocytic features; 36% were a/flus in 2 fna biopsies)  (Veracyte Inc)
90
Veracyte Inc a/flus (selective use; >1 without oncocytic features; 36% were a/flus in 2 fna biopsies)
General Characteristics of Included Studies
A/Flus (Selective Use; >1 Without Oncocytic Features; 36% Were A/Flus In 2 Fna Biopsies), supplied by Veracyte Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a/flus (selective use; >1 without oncocytic features; 36% were a/flus in 2 fna biopsies)/product/Veracyte Inc
Average 90 stars, based on 1 article reviews
a/flus (selective use; >1 without oncocytic features; 36% were a/flus in 2 fna biopsies) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
2 feature selection  (CH Instruments)
90
CH Instruments 2 feature selection
General Characteristics of Included Studies
2 Feature Selection, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/2 feature selection/product/CH Instruments
Average 90 stars, based on 1 article reviews
2 feature selection - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


General Characteristics of Included Studies

Journal: JAMA Otolaryngology-- Head & Neck Surgery

Article Title: Comparison of Postmarketing Findings vs the Initial Clinical Validation Findings of a Thyroid Nodule Gene Expression Classifier

doi: 10.1001/jamaoto.2019.1449

Figure Lengend Snippet: General Characteristics of Included Studies

Article Snippet: Baca et al, 2017 , January 2012-July 2016 , Brigham & Women's Hospital , No , Academic , No , Yes/Yes d , COI with Veracyte , A/FLUS (selective use; >1 cm, without oncocytic features; 36% were A/FLUS in 2 FNA biopsies).

Techniques: Biomarker Discovery